Literature DB >> 21925260

Single-trial conditioning in a human taste-endotoxin paradigm induces conditioned odor aversion but not cytokine responses.

Jan-Sebastian Grigoleit1, Jennifer S Kullmann, Anne Winkelhaus, Harald Engler, Alexander Wegner, Florian Hammes, Reiner Oberbeck, Manfred Schedlowski.   

Abstract

Immunological responses to bacterial endotoxin can be behaviorally conditioned in rodents. However, it is unclear whether an acute systemic inflammatory response can be behaviorally conditioned in humans. Thus, in a double-blind placebo-controlled study, 20 healthy, male subjects received either a single injection of lipopolysaccharide (LPS) or saline together with a novel tasting beverage (conditioned stimulus, CS). Five days later, all subjects received a saline injection and were re-exposed to the CS. Blood was drawn prior to as well as 0.5, 1.5, 3, 4, 6, and 24 h after LPS administration or CS re-exposure. Endotoxin administration led to transient increases in plasma concentrations of interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF)-α and to a significant rise in body temperature. Sole presentation of the CS during evocation did induce neither alterations in body temperature nor changes in plasma cytokine levels. However, subjects in the experimental group rated the smell of the CS significantly more aversive compared to the control group. Employing endotoxin as a US in a single trial taste-immune conditioning paradigm in humans shows a behaviorally conditioned smell aversion but no learned alterations in cytokine levels.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21925260     DOI: 10.1016/j.bbi.2011.09.001

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  8 in total

1.  Plasma cortisol response cannot be classically conditioned in a taste-endocrine paradigm in humans.

Authors:  Liubov Petrakova; Karoline Boy; Marisa Kügler; Sven Benson; Harald Engler; Lars Möller; Manfred Schedlowski
Journal:  Psychopharmacology (Berl)       Date:  2017-08-13       Impact factor: 4.530

Review 2.  Psycho-Neuro-Endocrine-Immunological Basis of the Placebo Effect: Potential Applications beyond Pain Therapy.

Authors:  Ángel Ortega; Juan Salazar; Néstor Galban; Milagros Rojas; Daniela Ariza; Mervin Chávez-Castillo; Manuel Nava; Manuel E Riaño-Garzón; Edgar Alexis Díaz-Camargo; Oscar Medina-Ortiz; Valmore Bermúdez
Journal:  Int J Mol Sci       Date:  2022-04-11       Impact factor: 6.208

3.  Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission.

Authors:  Alan Prossin; Alisa Koch; Phillip Campbell; Geoffroy Laumet; Christian S Stohler; Robert Dantzer; Jon-Kar Zubieta
Journal:  Mol Psychiatry       Date:  2021-10-29       Impact factor: 13.437

4.  Diurnal Variation of Circulating Interleukin-6 in Humans: A Meta-Analysis.

Authors:  Gustav Nilsonne; Mats Lekander; Torbjörn Åkerstedt; John Axelsson; Michael Ingre
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

Review 5.  So Many Faces, Phases, and Facets, Sickness Behavior Beyond Disciplines.

Authors:  Jan Pieter Konsman
Journal:  Front Psychiatry       Date:  2021-02-25       Impact factor: 4.157

6.  Inflammation-induced pain sensitization in men and women: does sex matter in experimental endotoxemia?

Authors:  Alexander Wegner; Sigrid Elsenbruch; Laura Rebernik; Till Roderigo; Elisa Engelbrecht; Marcus Jäger; Harald Engler; Manfred Schedlowski; Sven Benson
Journal:  Pain       Date:  2015-10       Impact factor: 7.926

7.  Conditioning cortisol in humans: design and pilot study of a randomized controlled trial.

Authors:  J Tekampe; H van Middendorp; F C G J Sweep; S H P P Roerink; A R M M Hermus; A W M Evers
Journal:  Pilot Feasibility Stud       Date:  2019-01-18

8.  Antipruritic Placebo Effects by Conditioning H1-antihistamine.

Authors:  Stefanie H Meeuwis; Henriët van Middendorp; Gustavo Pacheco-Lopez; Maarten K Ninaber; Adriana P M Lavrijsen; Nic van der Wee; Dieuwke S Veldhuijzen; Andrea W M Evers
Journal:  Psychosom Med       Date:  2019 Nov/Dec       Impact factor: 4.312

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.